AttributesValues
type
value
  • OBJECTIVE: Mortality from coronavirus disease 2019 (COVID‐19) is increased in COPD patients. Furthermore, higher body mass index (BMI) is related to severe disease. SARS‐CoV‐2 utilises angiotensin converting enzyme 2 (ACE2) to gain cellular entry. METHODS: We have investigated whether ACE2 bronchial epithelial expression is increased in COPD patients who are overweight compared to those who are not by RNA sequencing. RESULTS: We observed increased ACE2 expression in COPD patients who are overweight (mean BMI 29 kg/m(2)) compared to those notoverweight (mean BMI 21 kg/m(2)) (p=0.004). CONCLUSION: Increased ACE2 expression may cause increased SARS‐CoV‐2 infection of the respiratory tract. COPD patients who are overweight may be at greater risk of developing severe COVID‐19.
subject
  • Pfizer
  • American companies established in 1849
  • Publicly traded companies based in New York City
  • Orphan drug companies
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software